IL1B and Venous thrombosis: In the Canakinumab Anti-inflammatory Thrombosis Outcomes Trial (CANTOS), a human monoclonal antibody (Canakinumab) that specifically inhibits IL-1β is tested to reduce recurrent vascular events whereas in the Cardiovascular Inflammation Reduction Trial (CIRT) methotrexate as a tumor necrosis factor α and interleukin-6 inhibitor is applied to postmyocardial infarction patients to examine the promising animal data showing a slowdown in atherosclerotic lesion progression in cholesterol-fed rabbits [73].